NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Canopy Growth Corporation ("Canopy" or "the Company") (NASDAQ:CGC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Canopy securities between May 30, 2024 and February 6, 2025, both dates inclusive (the "Class Period").

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN) and certain of its officers.

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and retains an option to co-develop and co-promote in the U.S. SAN FRANCISCO, June 02, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), …

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Red Cat Holdings, Inc. ("Red Cat" or "the Company") (NASDAQ:RCAT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Red Cat securities between March 18, 2022 and January 15, 2025, both dates inclusive (the "Class Period").

HESPERIA, CA / ACCESS Newswire / June 2, 2025 / 5E Advanced Materials, Inc.(NASDAQ:FEAM)(ASX:5EA) ("5E" or the "Company"), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, announced today that Chief Executive Officer Paul Weibel will present at the MicroCap Rodeo Conference on Wednesday, June 4, 2025, in New York City. In addition to the live presentation, management will host one-on-one meetings with investors registered to attend the event.

I seek high-yield stocks with a true margin of safety, not just eye-catching yields that hide payout risks or value traps. Arbor Realty Trust offers a 12.5% yield and turnaround potential, with improving fundamentals and a 45% 12-month total return target. Blue Owl Capital combines rapid fee and dividend growth, strong earnings, and a 4.8% yield, with a 40% return outlook over 12 months.

ENGLEWOOD CLIFFS, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today announced the completion of its previously announced merger with The First of Long Island Corporation (Nasdaq: FLIC) (“First of Long Island”), parent company of The First National Bank of Long Island. With the completion of the transaction, the combined company is operating under the ConnectOne brand, with approximately $14 billion in total assets, $11 billion in total deposits and $11 billion in total loans.

DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization.

WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (-1.13; p=0.0078) in patients without nasal polyps.

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. ("DoubleVerify" or "the Company") (NYSE:DV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DoubleVerify securities between November 10, 2023 and February 27, 2025, both dates inclusive (the "Class Period").

New York, New York--(Newsfile Corp. - June 2, 2025) - DigiAsia Corp. (NASDAQ: FAAS) ("DigiAsia" or the "Company"), a technology-first fintech platform, today announced that it has appointed D. Boral Capital as exclusive placement agent for its proposed capital raise of up to $100 million.

Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bakkt Holdings, Inc. ("Bakkt" or "the Company") (NYSE:BKKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bakkt securities between March 25, 2024 and March 17, 2025, both dates inclusive (the "Class Period").

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (Nasdaq: MRX) (“Marex”), the diversified global financial services platform, announces that it will be participating in a fireside chat at Piper Sandler's Global Exchange & Trading Conference. The presentation will be given by Ian Lowitt, Group Chief Executive Officer and will take place on Thursday, June 5th at 8:00 a.m.

Nokia partners with Andorix to accelerate private 5G for North American real estate, combining Nokia's wireless tech with Andorix's building expertise.

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year 1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD).

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

2 nd Gen Leasing Activity Continues to be Strong Over 750,000 SF of Leases Signed to Date in Second Quarter Includes over 300,000 SF of New Leases